BrainsWay Delivers Strong Q4 and Full Year 2024 Performance
BURLINGTON, Mass. and JERUSALEM - BrainsWay Ltd. (NASDAQ: BWAY) reported remarkable financial results for the fourth quarter and the entire year of 2024, showcasing a robust growth trajectory in revenue and operational advancements.
Highlights from Q4 2024
Impressive Revenue and Sales Growth
In the fourth quarter of 2024, BrainsWay achieved a record revenue of $11.4 million, marking a significant increase of 27% compared to the same period in 2023. This growth reflects the increasing demand for BrainsWay’s innovative Deep TMS™ systems, which have garnered substantial market interest.
Product Expansion and Clinical Trials
The company also shipped a net total of 75 Deep TMS™ systems during the quarter, representing a remarkable 25% increase compared to Q4 2023. Furthermore, the gross margin for Q4 2024 remained strong at 75%, indicating BrainsWay's commitment to efficient operations. With an operating income of $0.4 million and an adjusted EBITDA of approximately $1.4 million, the financial indicators highlight a strengthening position in the market.
Clinical Advancements
BrainsWay continued its dedication to advancing mental health treatment through ongoing clinical trials. Progress was made in its randomized multicenter U.S. clinical trial, which evaluates an accelerated treatment protocol for Deep TMS in patients suffering from major depressive disorder (MDD).
Full Year 2024 Milestones
Significant Revenue Increase
For the full year 2024, BrainsWay recorded a total revenue of $41 million, which represents a 30% year-over-year growth. The company's gross margin for the year also improved, staying at a healthy 75%, with the operating income rising to $1.4 million, a significant turnaround from the operating loss of $5 million in the previous year.
Net Income and Strategic Financing
In the same period, BrainsWay reported a net income of $2.9 million, a notable increase from the net loss of $4.2 million in 2023. The adjusted EBITDA for the year also showcased improvement, totaling approximately $4.5 million compared to an adjusted EBITDA loss of $2.4 million the previous year. Additionally, the company completed a $20 million strategic equity financing transaction with Valor Equity Partners, aligning with premier U.S. tech investors to enhance accessibility to its Deep TMS™ systems.
FDA Labeling and Market Expansion
Notably, BrainsWay received expanded FDA labeling for Deep TMS, allowing the treatment of late-life depression in a broader age range, thus increasing availability. The company has seen a significant rise in treatment for anxious depression through Deep TMS, a condition affecting millions of adults annually in the U.S. Furthermore, BrainsWay has strategically entered the Canadian market through a multi-year distribution agreement and is continuing to expand within U.S. mental health networks.
Looking Ahead to 2025
Future Revenue Guidance
BrainsWay provided a positive financial guidance forecast for the full year 2025, projecting revenues between $49 million and $51 million—a growth of 20% to 24% compared to 2024. The company anticipates sustained profitability and cash flow positivity, with operating income targets of 3% to 4% and adjusted EBITDA of 11% to 12%.
Leadership Insights
CEO Hadar Levy expressed optimism regarding the growth trajectory of BrainsWay. He emphasized the company's strong relationships with enterprise customers and its robust sales backlog, which are critical for future expansion. Mr. Levy underscored the exciting developments in the pipeline, including the next-generation Deep TMS 360™ system and enhanced treatment capabilities.
Frequently Asked Questions
1. What is BrainsWay's recent financial performance?
BrainsWay reported a revenue increase of 27% in Q4 2024 and strengthened its full-year revenue to $41 million, showing significant operational progress.
2. How has BrainsWay expanded its product offerings?
The company shipped 75 Deep TMS™ systems in Q4 2024, reflecting strong market demand and ongoing clinical advancements in mental health treatment protocols.
3. What are the future projections for BrainsWay?
For 2025, BrainsWay anticipates a revenue range of $49 million to $51 million, indicating sustained growth and profitability plans moving forward.
4. What clinical trials is BrainsWay involved in?
BrainsWay is conducting clinical trials evaluating the accelerated treatment protocol for Deep TMS for major depressive disorder and qualifying PTSD patients for treatment.
5. How is BrainsWay positioning itself in the mental health sector?
BrainsWay continues to innovate and expand its market presence, focusing on collaborations with health networks and enhancing access to its Deep TMS therapies.
